Breaks Categories: News

ThursdayAug 25, 2022 11:12 am

BioMedNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) to Participate in Upcoming H.C. Wainwright Global Investment Conference

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), will be participating in the H.C. Wainwright 24th annual Global Investment Conference; the elite event is slated for Sept. 12–14, 2022. CYBN CEO Doug Drysdale will present in a virtual fireside chat during the conference. The company announced that his presentation will be available starting Sept. 12 at 7 a.m. ET. An archived copy of the presentation will also be available on Cybin’s website following the event. To view the presentation, visit https://ibn.fm/OUzui   To view the full press release, visit https://ibn.fm/8aXqL About Cybin Inc. Cybin…

Continue Reading

ThursdayAug 18, 2022 11:09 am

BioMedNewsBreaks – Odyssey Health Inc. (ODYY) Achieves Positive Safety Outcomes for Concussion Drug in Multiple Ascending Dosing Trial

Odyssey Health (OTC: ODYY), formerly Odyssey Group International and a company focused on developing unique, life-saving medical products including a novel compound for the treatment of concussion, has completed safety measures for its phase I multiday ascending dosing (“MAD”) clinical trial. According to the announcement, the trial is designed to study PRV-002, the company’s proprietary drug to treat concussion; this phase involves healthy human subjects. The company noted that the MAD cohort I, which was conducted at Nucleus Network, a leading clinical research organization, indicated the drug was safe and well tolerated. That phase involved eight healthy human volunteers who…

Continue Reading

TuesdayAug 16, 2022 2:13 pm

BioMedNewsBreaks – Odyssey Health Inc. (ODYY) Featured on ‘Dr. Finance Live’ Podcast

Odyssey Health (OTC: ODYY), a company focused on developing unique, life-saving medical products, was featured on “Dr. Finance Live,” a podcast series focused on changing the way we think about economics and finance. NFL Hall of Famer Brett Favre and Dr. Jacob VanLandingham, head of drug development for Odyssey Health, joined the recent broadcast, hosted by best-selling author and entrepreneur Dr. Anthony M. Criniti IV (aka “Dr. Finance(R)”). During the interview, Favre discussed how his passion for uncovering a treatment for concussion led him to his current position as a member of Odyssey Health’s sports advisory board. “When I retired…

Continue Reading

TuesdayAug 16, 2022 1:34 pm

BioMedNewsBreaks – QSAM Biosciences Inc. (OTCQB: QSAM) Releases Q2 2022 Financial Report, Corporate Update

QSAM Biosciences (OTCQB: QSAM), a company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP, or CycloSam(R), for the treatment of bone cancer and related diseases, has reported on its financial results for Q2, the period ended June 30, 2022; the company also noted that progress has been shown in its phase 1 clinical program designed to evaluate CycloSam, its proprietary radiopharmaceutical drug candidate for the treatment of metastatic bone cancer. Specifically, the report noted that preliminary evaluation of the first patient dosed in the phase 1 trial suggests promising results with second patient dosing and completion of the first cohort of patients…

Continue Reading

TuesdayAug 16, 2022 11:46 am

BioMedNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Results of Annual Meeting of Shareholders

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM)”, today announced voting results for each of the matters presented at the company’s annual shareholders’ meeting. There were 71 shareholders represented in person or by proxy, holding 47,019,721 common shares, representing 28.3% of Cybin’s total issued and outstanding common shares as at the record date for the meeting held on Aug. 15, 2022. The announcement details voting results for each matter presented, including the appointment of Zeifmans LLP as auditor and election of directors. Each of the nominees listed in Cybin’s July 13 management information…

Continue Reading

MondayAug 15, 2022 12:27 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Q2 2022 Financial Results, Corporate Update

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system. The company today reported its financial results for the quarter ended June 30, 2022, and provided a clinical update of its anti-cancer drug candidates currently in development. “Within the past six months alone, we have executed on a number of clinical and operational advancements including expanding our global presence with clinical approvals in Spain, France and Switzerland to drive patient enrollment forward, as well as expanding eligibility for patients to participate in our…

Continue Reading

ThursdayAug 11, 2022 11:50 am

BioMedNewsBreaks – Odyssey Health Inc. (ODYY) Shares Favre Interview

Odyssey Health (OTC: ODYY), formerly Odyssey Group International and a company focused on developing unique, life-saving medical products including a novel compound for the treatment of concussion, is sharing an interview by NFL Hall of Famer Brett Favre. During the interview, hosted by Bubba, the Love Sponge(R), Favre talks about the many concussions he received while playing football. Earlier this week, Favre did another interview with ODYY head of drug development Dr. Jacob VanLandingham, in which he also talked about concussions. During the interview with Bubba, the Love Sponge, Favre explained that when he left the NFL years ago, he…

Continue Reading

WednesdayAug 10, 2022 12:28 pm

BioMedNewsBreaks – Odyssey Health Inc. (ODYY) Announces Positive Results from MAD Arm of Phase I Trial

Odyssey Health (OTC: ODYY), a company focused on developing unique, life-saving medical products, today announced the completion and safety findings from Cohort I of its Multi-Day Ascending Dosing (“MAD”) arm for its phase I clinical trial. The trial is administering PRV-002, Odyssey’s novel drug to treat concussion, to healthy human subjects. According to the update, MAD Cohort I subjects were dosed for five consecutive days, with the drug, PRV-002, safe and well tolerated. “As the head of drug development for the PRV-002 concussion treatment, I was very happy to see these positive safety results when dosing for multiple days,” said…

Continue Reading

TuesdayAug 09, 2022 12:50 pm

BioMedNewsBreaks – Odyssey Health Inc.’s (ODYY) Dr. Jacob VanLandingham, Brett Favre Featured in ‘Get Authentic’ Podcast

Odyssey Health (OTC: ODYY), a company focused on developing unique, life-saving medical products, was featured in a recent episode of Get Authentic with Marques Ogden, a podcast series delivering honest, unfiltered and real-time stories from legendary athletes and industry leaders. NFL Hall of Famer Brett Favre and Dr. Jacob VanLandingham, head of drug development for Odyssey Health, joined the program, where Dr. VanLandingham discussed the unique selling proposition of Odyssey’s development pipeline. Favre also discussed the last days of his NFL career and his focus as a member of Odyssey’s sports advisory board. “My last play [in the NFL] was…

Continue Reading

TuesdayAug 09, 2022 12:37 pm

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Board Appointment, Changes

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, today announced the appointment of Nicole Lemerond to its board of directors, effective immediately. Lemerond is a financial executive with over 25 years of experience in investment management, private equity, investment banking and leveraged finance. Throughout her career, she has established and led health care groups at leading investment firms and has also worked at several large financial institutions, including Lehman Brothers and The Carlyle Group. Concurrent with Lemerond’s appointment, Adam Cutler has decided to transition off the board of directors. Cutler has served…

Continue Reading